A Study of BGM0504 Tablets in Healthy Chinese Subjects

Phase 1 Recruiting 144 enrolled BrightGene Bio-Medical Technology Co., Ltd. BrightGene Pharmaceutical (Suzhou) Co., LTD · collab

NaSingle-groupOpen-labelBasic science

Summary

A randomized, open-label, multiple-dose study to evaluate the effects of high-fat meals and different administration conditions (including water intake and fasting time) on the pharmacokinetics of BGM0504 tablets at a dose of 20mg in healthy Chinese participants and to assess its safety and tolerability.

Timeline

Start: 2026-03-26
Primary completion: 2026-09-30
Completion: 2026-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BGM0504	Unknown	20 mg	Oral

Indications

No indication recorded.